newsfilter
← Latest News
GlobeNewswire·

Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones

Company had $120.9 million of cash and cash equivalents as of March 12, 2021Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company...